MVM was founded in 1997 and manages several funds. MVM's latest fund totals more than $200 million. MVM has a global perspective on healthcare and maintains offices in Boston and London.
MVM invests broadly across the healthcare sector, including in specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and digital health.
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, is pleased to announce that it has agreed to acquire exclusive marketing rights to Nizoral, a medical, anti-dandruff shampoo brand, in Asia-Pacific from Janssen Pharmaceutica NV.
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.